← FDA DRUG APPROVALS

FDA ANDA · ANDA077533

TERBINAFINE

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA077533
TYPE
ANDA
ORIGINAL APPROVAL
2007-07-02
LATEST ACTION
2025-09-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TERBINAFINE HYDROCHLORIDEDiscontinued
TERBINAFINE HYDROCHLORIDE EQ 250MG BASE · TABLET · ORAL

Approval history

2025-09-11Labeling · Supplement 14 · standardAP
2025-09-11Labeling · Supplement 17 · standardAP
2016-01-10Labeling · Supplement 12 · standardAP
2016-01-10Labeling · Supplement 10 · standardAP
2012-07-12Labeling · Supplement 5 · standardAP
2011-09-20Labeling · Supplement 3AP
2007-07-02OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →